General Medical Officer (GMO) Manual: Clinical Section
Anaphylaxis
Department of the Navy
Bureau of Medicine and Surgery
Introduction
This chapter establishes procedures for recognizing and responding to an
anaphylactic or adverse reaction due to immunization, latex exposure, food or medication
ingestion, or an insect sting.
Overview
Anaphylaxis is a medical condition encountered by most medical providers during
their career. It is imperative that the provider be able to readily recognize this
condition and render appropriate treatment without hesitation. Immediate diagnoses and
expeditious treatment is very important.
Risk factors include:
-
Prior history (radiographic contrast material, exercise)
-
Multiple antibiotic sensitivity
-
Atopic history (food allergy, latex allergy, Beta blocker
use and possibly ACE
inhibitors may increase the difficulty of treatment.
Clinical manifestations of anaphylaxis:
-
The onset of anaphylaxis usually begins within 30 minutes after exposure to a causative
factor, although the onset may be delayed for several hours.
-
Once underway, the reaction usually progresses in an explosive manner, reaching peak
intensity within 1 hour.
-
The primary anaphylactic shock organs are the cutaneous, gastrointestinal, respiratory,
and cardiovascular systems.
-
Respiratory and cardiovascular events account for a majority of the mortality associated
with anaphylaxis.
-
Typical allergic symptoms.
-
Generalized itching or burning (especially on palms, soles, or groin area).
-
Sneezing or coughing.
-
Watering and itching of the eyes.
-
Hives or wheals.
-
Apprehension and flushing (especially around the face).
-
Tightness in chest or difficulty breathing.
-
Wheezing or shortness of breath.
-
Rapid, weak pulse. Low blood pressure. Shock.
-
Cyanosis.
At the first sign of an anaphylactic reaction, obtain vital signs and the anaphylaxis
treatment kit or Advanced Cardiac Life Support (ACLS) cart. If the patient has progressive
or severe symptoms such as diffuse hives, wheezing, airway obstruction, hypotension
(systolic BP less than 90), or shock, use protocol (3) immediately.
Protocol Procedures
-
Assess rapidly. Alert emergency personnel.
-
Place patient in a recumbent or trendelenburg position.
-
Place a tourniquet above injection/sting site(s) to delay absorption of the antigen.
Release the tourniquet for 1 to 2 minutes, every 10 minutes.
-
Establish an airway and provide supplemental oxygen.
-
Inject epinephrine (1:1000) 0.01 ml/kg (max. 0.3 to 0.5 cc) subcutaneously opposite the
site of injection every 20 minutes x 3. If asthma or wheezing is present, use 0.5 cc. Some
have advocated injection of 0.1 to 0.2 cc of epinephrine into the site of the inoculation
or sting. Do not consider this procedure if the allergic response site is on the head,
neck, hands, or feet. Prompt recognition of anaphylaxis and use of epinephrine is
critical. Epinephrine treatment delay can lead to the risk of fatality.
-
For pediatric patients administer epinephrine according to weight as follows:
10 lbs -
0.05cc |
30 lbs -
0.14cc |
50 lbs -
0.23cc |
15 lbs -
0.07cc |
35 lbs -
0.16cc |
55 lbs -
0.25cc |
20 lbs -
0.09cc |
40 lbs -
0.18cc |
60 lbs -
0.27cc |
25 lbs -
0.11cc |
45 lbs -
0.20cc |
65 lbs -
0.30cc |
-
Continuously monitor vital signs, maintain an open airway, establish
intravenous (IV) access, and attach a cardiac monitor. Treat for shock if present.
-
Give IV Ringers
Lactate: 1 to 2 liters (or 20 ml/kg for children)
-
Give dopamine 2 - 20 m g/kg/min, only if there
is difficulty in maintaining an adequate blood pressure.
[Mix 800 mg in 500 cc D5W to make solution of 1600 m
g/ml. For a 50 kg patient:
5 m g/kg/min = 9.4 microdrops/min,
10 m g/kg/min = 19 microdrops/min,
15 m g/kg/min = 28 microdrops/min,
20 m g/kg/min = 37.5 microdrops/min.]
Other recommendations as
needed include the following:
-
Give Diphenhydramine (Benadryl), 1.25 mg/kg (max. 50 mg) IV over 3 to 5 minutes. THIS IS
NOT A SUBSTITUTE FOR EPINEPHRINE.
-
Give Cimetidine (Tagamet), 5 mg/kg (maximum 300 mg) IV over 3 to 5 minutes.
-
Give Aminophyline, 5 mg/kg IV over 20 minutes. Then give 0.5 to 1.0 mg/kg/hr for severe
bronchospasm, if blood pressure (BP) and pulse are stable.
-
Glucagon: 1 to 2 mg IV bolus, with continuous infusion of 1 to 5 mg per hour if the
patient is not responding to epinephrine due to beta-blocker use.
Late phase reactions
It is important to realize that some patients will resolve their anaphylaxis only
to have a spontaneous recurrence 8 to 24 hours later.
-
Bronchodialators prevent the early phase, not the late phase.
-
Corticosteroids may prevent the late, but not the early phase.
-
Cromolyn prevents the early and late phases.
Corticosteroids given during the initial phase of anaphylaxis does not prevent the
appearance of recurrent or protracted anaphylaxis. Steroids may lessen the chances or
decrease the intensity of recurrence, but cannot be relied upon to eliminate this
response. However, in severe reactions, it is reasonable to start steroids early to modify
or perhaps prevent protracted or recurrent symptoms. The dose for Methylprednisolone is 2
mg/kg, followed by 1 mg/kg every 6 hours.
Individuals who have experienced an anaphylactic episode require 12 to 24 hours of
observation.
All persons with known or suspected anaphylactic episodes require a careful history and
clinical evaluation in consultation with Internal Medicine or Allergy. Patients should
carry epinephrine and Medic Alert identification.
Submitted by CAPT Jay R. Montgomery, MC, USN, MED-22, Surface
Warfare Medicine, BUMED, Washington, D.C. (1999). Revised by CAPT J.E. Murnane III, MC,
USN, Allergy/Immunology Specialty Leader, Allergy/Immunology Clinic, Naval Medical Center
Portsmouth, Portsmouth, VA (1999).
Approved for public release; Distribution is unlimited.
The listing of any non-Federal product in this CD is not an
endorsement of the product itself, but simply an acknowledgement of the source.
Operational Medicine 2001
Health Care in Military Settings
Bureau of Medicine and
Surgery
Department of the Navy
2300 E Street NW
Washington, D.C
20372-5300 |
Operational
Medicine
Health Care in Military Settings
CAPT Michael John Hughey, MC, USNR
NAVMED P-5139
January 1, 2001 |
United States Special Operations Command
7701 Tampa Point Blvd.
MacDill AFB, Florida
33621-5323 |
This web version is provided by
The Brookside Associates Medical Education
Division. It contains original contents from the official US Navy
NAVMED P-5139, but has been reformatted for web access and includes advertising
and links that were not present in the original version. This web version has
not been approved by the Department of the Navy or the Department of Defense.
The presence of any advertising on these pages does not constitute an
endorsement of that product or service by either the US Department of Defense or
the Brookside Associates. The Brookside Associates is a private organization,
not affiliated with the United States Department of Defense.
Contact Us · ·
Other
Brookside Products
|